Journals / Retina-Vitreus / 2014 / Cilt: 22 - Sayı: 4

The results of vfq-25 and gazi vfq-10 after single dose of ıntravitreal anti-vegf treatment

Tek doz intravitreal anti-vegf enjeksiyonu öncesi ve sonrası vfq-25 ve gazi vfq-10 anket sonuçları

Pages
297–301
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Because it is more understandable and practical than VFQ-25, Gazi VFQ-10 seems to be appropriate for clini- cal use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To examine the reliability of the life quality questionnaire Gazi VFQ-10 which we composed to make a shorter and understandable form of National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25) that is worldwidely used and investigate their correlation.
📊
Key Findings & Data:Material and Method: 26 patients who’ve been planned to take intravitreal anti VEGF injections because of age related macular degeneration, choroidal neovascular membrane of various causes, diabetic macular edema, vein occlusion were included.
💡
Conclusion & Impact:Conclusion: Because it is more understandable and practical than VFQ-25, Gazi VFQ-10 seems to be appropriate for clini- cal use.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To examine the reliability of the life quality questionnaire Gazi VFQ-10 which we composed to make a shorter and understandable form of National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25) that is worldwidely used and investigate their correlation. Material and Method: 26 patients who’ve been planned to take intravitreal anti VEGF injections because of age related macular degeneration, choroidal neovascular membrane of various causes, diabetic macular edema, vein occlusion were included. They were given VFQ-25 and Gazi VFQ-10 questionnaires at first visit. One month after the intravitreal injec- tion, following routine ophthalmologic examination, these questionnaires were given again. The changes in scores of these questionnaires after treatment were detected and the correlation between visual acuity changes were investigated. Results: 17 men, 9 women were participated and the mean age was 62.92±10.3 (40-80). The best corrected visual acuity ( BCVA) was 0.71±0.5 logMAR before treatment and 0.68±0.5 logMAR at the first month(p>0.05). Pretreatment general average VFQ-25 score was 60.7±20.3 (27.5-94.3) and 61.36±21.06 (25.7-94.46) at the first month after treatment (p>0.05). For Gazi VFQ-10 average score was 2.38±0.78 at the first visit and 2.65±0.85 at the first month (p: 0.038). Pretreatment and after treatment scores of VFQ-25 and Gazi VFQ-10 had significant correlation(before treatment r:0.934, p<0.001; after treatment r:0.727, p<0.001).But the changes in scores were not correlated with the change of BCVA for any of these ques- tionnaires. Conclusion: Because it is more understandable and practical than VFQ-25, Gazi VFQ-10 seems to be appropriate for clini- cal use.

Özet

Amaç: Bu çalışmada uluslararası alanda yaygın kullanım yeri bulan National Eye Institute Visual Functioning Question- naire-25 (VFQ-25) ile; daha kısa, daha anlaşılır olduğunu düşündüğümüz anketimizin(Gazi VFQ-10) güvenilirliğini karşı- laştırmak ve VFQ-25 ile korelasyonunu değerlendirmek amaçlandı. Gereç ve Yöntem: Senil makula dejenerasyonu veya diğer sebeplere bağlı koroid neovasküler membran, diabetik makula ödemi, ven tıkanıklığı tanıları ile kliniğimize başvuran ve intravitreal anti :VEGF enjeksiyonu endikasyonu olan 26 hasta çalışmaya dahil edildi. Bu hastalara ilk başvuruları sırasında Gazi VFQ-10 ve VFQ-25 anketleri verilerek doldurmaları is- tendi. İntravitreal ranibizumab/bevacizumab enjeksiyonundan 1 ay sonra görme keskinlikleri ölçümü ve rutin oftalmolojik muayene sonrası anketler tekrarlandı. Tedavi öncesi ve sonrası elde edilen sonuçlar karşılaştırılıp, görme keskinliğindeki değişim ile korelasyonları incelendi. Bulgular: Çalışmaya katılan hastaların 17’si erkek, 9’u kadındı ve ortalama yaş 62.92±10.3 (40-80) idi. İlk vizitte orta- lama görme keskinliği 0.71±0.5 logMAR olarak saptanırken, enjeksiyon sonrası 1. ayda 0.68±0.5 logMAR olarak bulundu (p>0.05). Enjeksiyon öncesi genel ortalama VFQ-25 skoru 60.7±20.3 (27.5-94.3) bulunurken 1. ayda bu değer 61.36±21.06 (25.7-94.46) idi (p>0.05). Gazi VFQ-10 ortalama skor da ilk vizite 2.38±0.78 iken, 1 ay sonra 2.65± 0.85 olarak bulundu ve bu artış istatistiksel olarak anlamlı idi (p:0.038). VFQ-25 için tedavi öncesi ve sonrası hesaplanan skorlar ile Gazi VFQ-10’ daki aynı dönem ortalama skorlar arasında korelasyon olduğu saptandı (tedavi öncesi r:0.934, p<0.001; tedavi sonrası r:0.727, p<0.001). Her iki anketin skor değişikliği görme keskinliğindeki değişim ile korele değildi. Sonuç: Gazi VFQ-10, VFQ-25’ten daha anlaşılır olduğu ve daha az zaman aldığı için klinik kullanım için uygun gibi gö- zükmektedir.

🔖

Cite This Article

KEPEZ, B. Y., YALÇIN, N. G., ÖZDEK, Ş., HASANREİSOĞLU, B. (2014). The results of vfq-25 and gazi vfq-10 after single dose of ıntravitreal anti-vegf treatment. Retina-Vitreus, Cilt: 22 - Sayı: 4, 297–301. https://ajindex.com/articles/308135

References (1)

  1. Orr P, Rentz A, Margolis M et al. Validation of national eye institute visual function questionnaire -25 in age re- lated macular degeneration. Invest Ophthalmol Vis.Sci 2011;52:3354-9. 2.Vitale S, Goodman L, Reed G et al. Comparison of the NEI- VFQ and OSDI questionnaires in patients with Sjögren’s syndrome-related dry eye. Health and Quality of Life Out- comes 2004;2:44. 3.Revicki D, Rentz A, Harnam N et al. Reliability and valid- ity of the national eye institute visual function question- naire -25 in patients with age related macular degenera- tion. Invest Ophthalmol Vis Sci 2010;51:712-7. 4.Mangione CM, Lee PP, Gutierrez PR et al. Development of the 25-item national eye institute visual function question- naire. Arch Ophthalmol 2001;119:1050-8. 5.Toprak AB, Eser E, Guler C,Görme ile ilgili sağlıkta yaşam kalitesi ölçekleri ve ulusal göz hastalıkları enstitüsü görme işlevi ölçeğinin (NEI-VFQ) Türkçe çevirisi, T. Oft. Gaz 2005;35:453-9. 6. Brown DM, Kaiser PK, Michels M et al. Ranibizumab ver- sus verteporfirin for neovascular age-related macular de- generation. N Eng J Med 2006;355:1432-44. 7.Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006;355:1419-31. 8.Suner I, Kokame G, Yu E et al. Responsiveness of NEI VFQ-25 to changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical Trials. Invest Ophthalmol Vis Sci 2009;50:3629-35. 9.Owen CG, Rudnicka AR, Smeeth L et al. Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population? BMC Ophthalmol 2006;6:24. 10.Ryan B, Court H, Margrain TH. Measuring low vision ser- vice outcomes: Rasch analysis of the seven-item National Eye Institute Visual Function Questionnaire. Optom Vis Sci 2008;85:112-21.